Fluvoxamine as an adjunct to promote methadone dose optimization

Addictive Disorders and their Treatment

Volumn 2, Issue 3, 2003, Pages 85-89

  DeMaria Jr , Peter A ^a   Patkar, Ashwin A ^b   Vassos, Katherine ^b  

^a Sullivan Hall   (United States)

^b NONE

Author keywords

Drug interactions; Fluvoxamine; Methadone

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BUTALBITAL; CYTOCHROME P450; DIAZEPAM; FLUVOXAMINE; LAMIVUDINE; METHADONE; MIDAZOLAM; NEFAZODONE; NEVIRAPINE; PARACETAMOL; SEROTONIN UPTAKE INHIBITOR; STAVUDINE; TRIAZOLAM;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

EID: 0043238072     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132576-200302030-00004     Document Type: Article

References (39)

1. Dole V, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:646-650.
2. Zweben J, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. West Journal of Medicine. 1990;152:588-599.
3. D'Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA. 1992;267:281-282.
4. Holmstrand J, Anggard E, Gunne L. Methadone maintenance: plasma levels and therapeutic outcomes. Clinical Pharmocol Ther. 1978;23(2):175-180.
5. Loimer N, Schmid R. The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend. 1992;30:241-246.
6. Strain EC, Stitzer ML, Liebson IA, et al. Methadone dose and treatment outcome. Drug Alcohol Depend. 1993;33:105-117.
7. Strain EC, Bigelow GE, Liebson IA, et al. Moderate- vs. high-dose methadone in the treatment of opioid dependence. JAMA. 1999;281(11):1000-1005.
8. Borg L, Ho A, Peters JE, et al. Availability of reliable serum methadone determination for management of symptomatic patients. J Addict Dis. 1995;14(3):83-96.
9. Bell J, Seres V, Bowman P, et al. The use of serum levels in patients receiving methadone maintenance. Clinical Pharmacology Therapy. 1988;43:623-629.
10. Kreek MJ. Plasma and urine levels of methadone. N Y State J Med. 1973;73(23):2773-2777.
11. Tennant FS. Inadequate plasma concentrations in some high-dose methadone maintenance patients. Am J Psych. 1987;144 (10):1349-1350.
12. DeMaria P. Methadone drug interactions. J. of Maintenance in the Addictions. In press.
13. Nilsson MI, Widerlov E, Meresaar U, et al. Effect of urinary pH on the disposition of methadone in man. Eur J. of Clin. Pharm. 1982;22:337-342.
14. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzymes in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996;9(2):365-373.
15. Eap CB, Bertschy G, Baumann P, et al. High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psych. 1998;55:89-90.
16. Payte JT, Khuri E. Principles of methadone dose determination. In: Parrino M, ed. State Methadone Guidelines, TIP series, #1. Rockville, MD: U.S. Department of Health and Human Services, Center for Substance Abuse Treatment; 1993:47-58.
17. Horns WH, Rado M, Goldstein A. Plasma levels and symptoms complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther. 1975;17(6):636-649.
18. Ball J, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991.
19. Caplehorn J, Bell J. Methadone dosage and retention of patients in methadone maintenance treatment. Med J of Australia. 1991;154:195-199.
20. Wolff K, Sanderson M, Hay AWM, et al. Methadone concentration in plasma and their relationship to drug dosage. Clin Chem. 1991;37(2):205-209.
21. Dyer KR, Foster DJR, White JM, et al. Steady state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration effect relationships. Clin Pharmacol Ther. 1999;65:685-694.
22. Foster DJR, Somogyi AA, Dyer KR, et al. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000;50:427-440.
23. Hiltumen AJ, Beck O, Hjemdahl P, et al. Rated well-being in relation to plasma concentrations of 1- and d-methadone in satisfied and dissatisfied patients in methadone maintenance treatment. Psychopharmacology (Berl). 1999;143:385-393.
24. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31(6):455-469.
25. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes and some newer antidepressants: kinetics, metabolism and drug interactions. J Clin Psychopharm. 1999;19(Suppl 1):23S-35S.
26. Bertschy G, Baumann P, Eap CB, et al. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit. 1994;16:42-45.
27. DeMaria PA, Serota RD. A therapeutic use of the methadone fluvoxamine drug interaction. J Addict Dis. 1999;18(4):5-12.
28. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharm. 2001;21(2):229-234.
29. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
30. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957-962.
31. Pinzani V, Faucherre V, Peyriere H, et al. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother. 2000;34:405-407.
32. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for the use of nevirapine to treat injection drug users. Clin Infect Dis. 2001;33(9):1595-1597.
33. Rabkin JG, Johnson J, Lin SH, et al. Psychopathology in male and female HIV-positive and negative injecting drug users: longitudinal course over 3 years. AIDS. 1997;Mar 15;11(4):507-515.
34. Lui SJ, Wang RIH. Case report of barbiturate induced enhancement of methadone metabolism and withdrawal syndrome. Amer J of Psych. 1984;141:1287.
35. Manna V, Bolino F, DiCicco L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache. 1994;Jan;34(1):44-49.
36. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994;Sep;34(8):476-478.
37. Luvox (fluvoxamine maleate) current prescribing information. Marietta, CA: Solvay Pharmaceutical Inc.; September, 2000.
38. Iguchi MY, Handelsman L, Bickel WK, et al. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 1993;32:257-266.
39. Hobbs WR, Rall TW, Verdoorn TA. Hypnotics and sedatives: ethanol. In: Hardman JG, Limberg LF, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:Chapter 17.